FY2025 EPS Estimates for Cytokinetics Cut by B. Riley

Cytokinetics, Incorporated (NASDAQ:CYTK) – Research analysts at B. Riley decreased their FY2025 earnings estimates for Cytokinetics in a note issued to investors on Monday, September 22nd. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings of ($5.72) per share for the year, down from their prior estimate of ($5.62). B. Riley has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics’ Q4 2025 earnings at ($1.64) EPS, FY2026 earnings at ($6.04) EPS, FY2027 earnings at ($5.46) EPS, FY2028 earnings at ($3.39) EPS and FY2029 earnings at $0.21 EPS.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.12) EPS for the quarter, topping analysts’ consensus estimates of ($1.34) by $0.22. The firm had revenue of $66.77 million during the quarter, compared to the consensus estimate of $1.95 million. The business’s revenue for the quarter was up 26727.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.31) earnings per share.

Several other equities analysts also recently issued reports on CYTK. HC Wainwright restated a “buy” rating and set a $120.00 price objective on shares of Cytokinetics in a report on Monday. JPMorgan Chase & Co. cut their price objective on shares of Cytokinetics from $71.00 to $53.00 and set an “overweight” rating on the stock in a report on Monday, June 9th. Evercore ISI upped their price objective on shares of Cytokinetics from $60.00 to $80.00 and gave the company an “outperform” rating in a report on Wednesday, September 3rd. Mizuho cut their price objective on shares of Cytokinetics from $103.00 to $84.00 and set an “outperform” rating on the stock in a report on Thursday, May 29th. Finally, Raymond James Financial assumed coverage on shares of Cytokinetics in a report on Wednesday, July 30th. They set a “market perform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $75.71.

Cytokinetics Stock Performance

Shares of Cytokinetics stock opened at $47.83 on Wednesday. The company has a market capitalization of $5.72 billion, a PE ratio of -9.38 and a beta of 0.62. The company has a 50-day simple moving average of $41.56 and a two-hundred day simple moving average of $38.18. Cytokinetics has a one year low of $29.31 and a one year high of $59.39.

Insider Activity at Cytokinetics

In related news, Director Edward M. Md Kaye sold 6,756 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $50.00, for a total value of $337,800.00. Following the sale, the director owned 23,230 shares in the company, valued at $1,161,500. This represents a 22.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Fady Ibraham Malik sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 23rd. The shares were sold at an average price of $49.28, for a total value of $98,560.00. Following the completion of the sale, the executive vice president owned 140,610 shares in the company, valued at approximately $6,929,260.80. This represents a 1.40% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,756 shares of company stock worth $1,452,550 over the last quarter. Insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Cytokinetics

A number of large investors have recently bought and sold shares of the company. Thrivent Financial for Lutherans boosted its position in Cytokinetics by 1.6% in the second quarter. Thrivent Financial for Lutherans now owns 28,119 shares of the biopharmaceutical company’s stock valued at $929,000 after buying an additional 449 shares during the last quarter. Hudson Bay Capital Management LP boosted its position in Cytokinetics by 7.1% in the 2nd quarter. Hudson Bay Capital Management LP now owns 157,786 shares of the biopharmaceutical company’s stock worth $5,213,000 after purchasing an additional 10,523 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its position in Cytokinetics by 13.8% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 78,544 shares of the biopharmaceutical company’s stock worth $2,596,000 after purchasing an additional 9,512 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Cytokinetics by 29.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,086 shares of the biopharmaceutical company’s stock worth $366,000 after purchasing an additional 2,551 shares in the last quarter. Finally, Exome Asset Management LLC boosted its position in Cytokinetics by 43.9% in the 2nd quarter. Exome Asset Management LLC now owns 115,817 shares of the biopharmaceutical company’s stock worth $3,827,000 after purchasing an additional 35,334 shares in the last quarter.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.